Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 910

Similar articles for PubMed (Select 21333232)

1.

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N.

Health Technol Assess. 2011 Feb;15(10):i-xxi, 1-329. doi: 10.3310/hta15100. Review.

2.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

3.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

4.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

5.

Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.

Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce IN, Sculpher M, Woolacott N.

Pharmacoeconomics. 2012 Apr;30(4):257-70. doi: 10.2165/11595920-000000000-00000. Review.

PMID:
22283690
6.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.

Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060. Review.

7.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF.

Health Technol Assess. 2011 Mar;15(14):1-278. doi: 10.3310/hta15140. Review.

8.

Golimumab for the treatment of psoriatic arthritis.

Yang H, Epstein D, Bojke L, Craig D, Light K, Bruce I, Sculpher M, Woolacott N.

Health Technol Assess. 2011 May;15 Suppl 1:87-95. doi: 10.3310/hta15suppl1/10. Review.

9.

Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis.

Bojke L, Epstein D, Craig D, Rodgers M, Woolacott N, Yang H, Sculpher M.

Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv39-iv47. doi: 10.1093/rheumatology/ker245.

10.

Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis.

Cawson MR, Mitchell SA, Knight C, Wildey H, Spurden D, Bird A, Orme ME.

BMC Musculoskelet Disord. 2014 Jan 20;15:26. doi: 10.1186/1471-2474-15-26. Review.

11.

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.

12.

The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.

Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ.

Rheumatology (Oxford). 2007 Nov;46(11):1729-35.

13.

Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.

Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M.

J Med Econ. 2013;16(4):479-89. doi: 10.3111/13696998.2013.768530. Epub 2013 Feb 7.

PMID:
23339434
14.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review.

Woolacott NF, Khadjesari ZC, Bruce IN, Riemsma RP.

Clin Exp Rheumatol. 2006 Sep-Oct;24(5):587-93. Review.

PMID:
17181932
15.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

16.

Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.

Cummins E, Asseburg C, Punekar YS, Shore E, Morris J, Briggs A, Fenwick E.

Value Health. 2011 Jan;14(1):15-23. doi: 10.1016/j.jval.2010.10.016.

PMID:
21211482
18.

TNF-alpha inhibitors for ankylosing spondylitis.

Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2015 Apr 18;4:CD005468. doi: 10.1002/14651858.CD005468.pub2.

PMID:
25887212
19.

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.

Cochrane Database Syst Rev. 2014 Sep 29;9:CD010455. doi: 10.1002/14651858.CD010455.pub2. Review.

PMID:
25264908
20.

Eliciting distributions to populate decision analytic models.

Bojke L, Claxton K, Bravo-Vergel Y, Sculpher M, Palmer S, Abrams K.

Value Health. 2010 Aug;13(5):557-64. doi: 10.1111/j.1524-4733.2010.00709.x. Epub 2010 Mar 22.

PMID:
20345548
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk